Association of International Research-based Pharmaceuticals Manufacturers (SIFFA) is an open voluntary public organisation. The goal of SIFFA is to promote the operations of pharmaceutical companies in Latvia, to improve the healthcare quality, to increase the level of education and expertise of physicians, chemists and general public, as well as to promote and support the organised pharmaceutical market development in cooperation with governmental authorities.

The objectives of SIFFA are to recommend its members the optimal solution of their problems, to respond adequately to any situation whenever any person’s actions infringe on the rights and legitimate interests of an SIFFA member, to use the whole range of possibilities to solve the existing problems.

SIFFA was founded in January 1996 and initially united five representatives of foreign pharmaceutical firms operating in Latvia (Glaxo Welcome, Merck Sharp & Dohme, Boehringer Ingelheim, Schering and Eli Lilly). At present, SIFFA unites 20 members, representing: AbbVie, Amgen, AstraZeneca, Bayer, Berlin–Chemie/Menarini, Boeringer Ingelheim, Biogen, Eli Lilly, Gedeon Richter, Ipsen, Johnson & Johnson, Merck Serono, Merck Sharp & Dohme, Novartis, Novo Nordisk, Pfizer, Sanofi, Santen, Servier International, Takeda.

SIFFA members are the world’s biggest manufacturers of pharmaceutical products, by their turnover and capitalisation also ranking among the world’s biggest companies in general. The Association members are engaged in both medicine production and development and research of new medicines.